Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

(Alliance News) - GSK PLC on Friday said its drug Blenrep has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use.

GSK (NYSE:GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

The recommendation by the Committee for Medicinal Products for Human Use--also known as CHMP--follows the approval of Blenrep combinations by the U.K.'s Medicines and Healthcare products Regulatory ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

LONDON (dpa-AFX) - British drug maker GSK plc (GSK.L, GSK) announced Monday the approval of Blenrep combinations by Japan's Ministry of Health, Labour and Welfare or MHLW for the treatment of ...

Second major approval for Blenrep combinations, with more expected in 2025 This is the second major regulatory approval for Blenrep combinations for the treatment of relapsed or refractory multiple ...